REXAHN PHARMACEUTICALS, INC. 4
4 · REXAHN PHARMACEUTICALS, INC. · Filed Jan 12, 2015
Insider Transaction Report
Form 4
Ahn Chang Ho
DirectorChairman & CEO
Transactions
- Sale
Common Stock
2015-01-08$0.90/sh−80,000$72,032→ 6,010,000 total - Sale
Common Stock
2015-01-09$0.92/sh−186,212$170,477→ 6,010,000 total - Exercise/Conversion
Common Stock
2015-01-12$0.80/sh+48,444$38,755→ 6,058,444 total - Exercise/Conversion
Stock Option (right to purchase)
2015-01-12−48,444→ 549,151 totalExercise: $0.80Exp: 2015-01-20→ Common Stock (48,444 underlying) - Exercise/Conversion
Stock Option (right to purchase)
2015-01-09−186,212→ 597,595 totalExercise: $0.80Exp: 2015-01-20→ Common Stock (186,212 underlying) - Exercise/Conversion
Common Stock
2015-01-08$0.80/sh+80,000$64,000→ 6,090,000 total - Exercise/Conversion
Common Stock
2015-01-09$0.80/sh+186,212$148,970→ 6,196,212 total - Sale
Common Stock
2015-01-12$0.91/sh−48,444$44,263→ 6,010,000 total - Exercise/Conversion
Stock Option (right to purchase)
2015-01-08−80,000→ 783,807 totalExercise: $0.80Exp: 2015-01-20→ Common Stock (80,000 underlying)
Holdings
- 500,000(indirect: By Spouse)
Common Stock
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price of $0.9004 per share represents a weighted average of sales prices from $0.90 to $0.9098 per share. The reporting person undertakes to provide upon request of the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price of $0.9155 per share represents a weighted average of sales prices from $0.90 to $0.945 per share. The reporting person undertakes to provide upon request of the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]The price of $0.9137 per share represents a weighted average of sales prices from $0.90 to $0.9351 per share. The reporting person undertakes to provide upon request of the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F6]Options vested and became exercisable based on the following schedule: 300,000 on January 20, 2006, 300,000 on January 20, 2007, and 400,000 on January 20, 2008.